---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294264489.md"
description: "Corbus Pharmaceuticals (CRBP) shares fell 1.82% to $8.92, outperforming peers like Vanda and Fortress Biotech during a broad market decline. The stock remains significantly below its 52-week high of $20.56. Trading volume was notably lower than the 50-day average."
datetime: "2026-07-29T21:21:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294264489.md)
  - [en](https://longbridge.com/en/news/294264489.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294264489.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) slid 1.82% to $8.92 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.74% to 24,442.94 and Dow Jones Industrial Average falling 2.19% to 51,594.14.

Corbus Pharmaceuticals Holdings Inc. closed 56.61% short of its 52-week high of $20.56, which the company achieved on October 20th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc. (VNDA) fell 2.13% to $5.05, Fortress Biotech Inc. (FBIO) fell 1.18% to $3.35, and Viking Therapeutics Inc. (VKTX) fell 1.27% to $33.43.

Trading volume (263,499) remained 272,191 below its 50-day average volume of 535,690.

Data source: Dow Jones Market Data, FactSet. Data compiled July 29, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-29-26 1721ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visit](https://longbridge.com/en/news/294824963.md)
- [CSPC says FDA clears CRB-701 pivotal trial in second-line oropharyngeal cancer](https://longbridge.com/en/news/294208879.md)
- [BUZZ-PREVIEW: Merck Q2 revenue seen rising, deal to weigh on bottom line](https://longbridge.com/en/news/294728870.md)
- [BUZZ-Inovio Pharma plunges on planned equity offering](https://longbridge.com/en/news/294255408.md)
- [3,455 Shares in Ligand Pharmaceuticals Incorporated $LGND Bought by Hsbc Holdings PLC](https://longbridge.com/en/news/294479456.md)